Generale
Lupin Neurosciences si impegna a collaborare con gli operatori sanitari per sviluppare soluzioni basate sulla scienza che vadano al di là dell’accesso a opzioni terapeutiche che cambiano la vita ed ottimizzan la cura di pazienti affetti da malattie neurologiche sottoservite.
2024 Congresses
IDMC -14: The 14th International Myotonic Dystrophy Consortium Meeting, 09-13 April 2024, Nijmegen, The Netherlands
-
- Age, family history and genetic testing data from myotonic dystrophy patients and carers participating in ENSA survey
- ENSA:RevEal the burdeN on daily life for myotonic dyStrophy patients due to myotoniA: key findings of the ENSA surve
- Patient reported satisfaction in myotonic dystrophy management: ENSA international survey suggests benefits of Italian routine practice
8th International Myology Congress, 22-25 April, 2024, Paris, France
- Expert insights: A Delphi-driven neurologists’ panel: real-world mexiletine use in patients with myotonic disorders in Italy
- Development of an auto-questionnaire to measure the impact of non-dystrophic myotonia on patients’ daily lives
- Design and objective of HERCULES and ATLAS: randomised, double-blind, placebo-controlled, multi-centre Phase 3 study investigating once-daily mexiletine prolonged release in myotonic dystrophy types 1 and 2